Factors influencing immunologic response to hepatitis B vaccine in adults

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Yang, Shigui ^a   Tian, Guo ^a   Cui, Yuanxia ^a   Ding, Cheng ^a   Deng, Min ^a   Yu, Chengbo ^a   Xu, Kaijin ^a   Ren, Jingjing ^a   Yao, Jun ^b   Li, Yiping ^c   Cao, Qing ^a   Chen, Ping ^a   Xie, Tiansheng ^a   Wang, Chencheng ^a   Wang, Bing ^a   Mao, Chen ^d   Ruan, Bing ^a   Jiang, Tian'An ^e   Li, Lanjuan ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b ZHEJIANG PROVINCIAL CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^c Zhejiang Institute of Medical care Information Technology   (China)

^d CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^e ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B VACCINE;

ADULT; AGED; DRINKING BEHAVIOR; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNOLOGY; INNATE IMMUNITY; MALE; META ANALYSIS; MIDDLE AGED; PATHOGENICITY; REGRESSION ANALYSIS; VACCINATION; VIROLOGY;

ADULT; AGED; ALCOHOL DRINKING; FEMALE; HEPATITIS B; HEPATITIS B VACCINES; HEPATITIS B VIRUS; HUMANS; IMMUNITY, INNATE; MALE; MIDDLE AGED; REGRESSION ANALYSIS; VACCINATION;

EID: 84975801854     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep27251     Document Type: Article

References (58)

1. Lavanchy, D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. Journal of viral hepatitis 11, 97-107 (2004).
2. European Centre for Disease Prevention and Control. Hepatitis B and C in the EU neighbourhood: prevalence, burden of disease and screening policies. European Centre for Disease Prevention and Control. 56 p. doi: 10.2900/30933 (Stockholm, 2010).
3. Hahne, S. J. et al. Infection with hepatitis B and C virus in Europe: a systematic review of prevalence and cost-effectiveness of screening. BMC infectious diseases 13, 181, doi: 10.1186/1471-2334-13-181 (2013).
4. Keck, J. W. et al. Hepatitis B virus antibody levels 7 to 9 years after booster vaccination in Alaska native persons. Clinical and vaccine immunology: CVI 21, 1339-1342, doi: 10.1128/CVI.00263-14 (2014).
5. Bruce, M. G. et al. Antibody Levels and Protection After Hepatitis B Vaccine: Results of a 30-Year Follow-up Study and Response to a Booster Dose. The Journal of infectious diseases, doi: 10.1093/infdis/jiv748 (2016).
6. Yang, S. G. et al. Effectiveness of HBV vaccination in infants and prediction of HBV prevalence trend under new vaccination plan: findings of a large-scale investigation. PloS one 7, e47808, doi: 10.1371/journal.pone.0047808 (2012).
7. Su, F. H. et al. Hepatitis B seroprevalence and anamnestic response amongst Taiwanese young adults with full vaccination in infancy, 20 years subsequent to national hepatitis B vaccination. Vaccine 25, 8085-8090, doi: 10.1016/j.vaccine.2007.09.013 (2007).
8. Melhem, N. M., Rahhal, N., Charide, R., Kreidieh, K. & El-Khatib, R. Human immunodeficiency virus and viral hepatitis among high-risk groups: Understanding the knowledge gap in the Middle East and North Africa Region. World journal of hepatology 7, 2619-2630, doi: 10.4254/wjh.v7.i25.2619 (2015).
9. McGregor, I. A. Health and Communicable Disease in a Rural African Environment. Oikos 27, 180-192, doi: 10.2307/3543897 (1976).
10. Peto, T. J. et al. Efficacy and effectiveness of infant vaccination against chronic hepatitis B in the Gambia Hepatitis Intervention Study (1986-90) and in the nationwide immunisation program. BMC infectious diseases 14, 7, doi: 10.1186/1471-2334-14-7 (2014).
11. Fisman, D. N., Agrawal, D. & Leder, K. The effect of age on immunologic response to recombinant hepatitis B vaccine: a metaanalysis. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America 35, 1368-1375, doi: 10.1086/344271 (2002).
12. Zajac, B. A., West, D. J., McAleer, W. J. & Scolnick, E. M. Overview of clinical studies with hepatitis B vaccine made by recombinant DNA. The Journal of infection 13 Suppl A, 39-45 (1986).
13. Jilg, W., Schmidt, M. & Deinhardt, F. Vaccination against hepatitis B: comparison of three different vaccination schedules. The Journal of infectious diseases 160, 766-769 (1989).
14. Morris, C. A., Oliver, P. R., Reynolds, F. & Selkon, J. B. Intradermal hepatitis B immunization with yeast-derived vaccine: serological response by sex and age. Epidemiology and infection 103, 387-394 (1989).
15. Westmoreland, D., Player, V., Heap, D. C. & Hammond, A. Immunization against hepatitis B-what can we expect? Results of a survey of antibody response to immunization in persons 'at risk' of occupational exposure to hepatitis B. Epidemiology and infection 104, 499-509 (1990).
16. Guan, R., Tay, H. H., Choong, H. L., Yap, I. & Woo, K. T. Hepatitis B vaccination in chronic renal failure patients undergoing haemodialysis: the immunogenicity of an increased dose of a recombinant DNA hepatitis B vaccine. Annals of the Academy of Medicine, Singapore 19, 793-797 (1990).
17. Dahl-Hansen, E., Siebke, J. C., Froland, S. S. & Degre, M. Immunogenicity of yeast-derived hepatitis B vaccine from two different producers. Epidemiology and infection 104, 143-149 (1990).
18. Dentico, P. et al. Long-term immunogenicity safety and efficacy of a recombinant hepatitis B vaccine in healthy adults. European journal of epidemiology 8, 650-655 (1992).
19. Roome, A. J., Walsh, S. J., Cartter, M. L. & Hadler, J. L. Hepatitis B vaccine responsiveness in Connecticut public safety personnel. Jama 270, 2931-2934 (1993).
20. McMaster, K. R., 3rd, Roper, J. K. & Carter, J. B. Intradermal hepatitis B vaccination in a 300-bed primary care hospital: experience with a recombinant vaccine in a four-dose schedule. American journal of infection control 21, 283-288 (1993).
21. Jaiswal, S. B., Salgia, P. B., Sepaha, A. G. & Chitnis, D. S. Hepatitis B vaccine in patients on haemodialysis. Lancet 346, 317-318 (1995).
22. Bock, H. L. et al. Immunogenicity of a recombinant hepatitis B vaccine in adults. Archives of internal medicine 156, 2226-2231 (1996).
23. Averhoff, F. et al. Immunogenicity of hepatitis B Vaccines. Implications for persons at occupational risk of hepatitis B virus infection. American journal of preventive medicine 15, 1-8 (1998).
24. Cardell, K., Fryden, A. & Normann, B. Intradermal hepatitis B vaccination in health care workers. Response rate and experiences from vaccination in clinical practise. Scandinavian journal of infectious diseases 31, 197-200 (1999).
25. Ingardia, C. J., Kelley, L., Steinfeld, J. D. & Wax, J. R. Hepatitis B vaccination in pregnancy: factors influencing efficacy. Obstetrics and gynecology 93, 983-986 (1999).
26. Young, M. D. et al. Adult hepatitis B vaccination using a novel triple antigen recombinant vaccine. Hepatology 34, 372-376, doi: 10.1053/jhep.2001.26167 (2001).
27. Wolters, B., Junge, U., Dziuba, S. & Roggendorf, M. Immunogenicity of combined hepatitis A and B vaccine in elderly persons. Vaccine 21, 3623-3628 (2003).
28. Martins, R. M. et al. Multicenter study on the immunogenicity and safety of two recombinant vaccines against hepatitis B. Memorias do Instituto Oswaldo Cruz 99, 865-871, doi: S0074-02762004000800014 (2004).
29. Yen, Y. H. et al. Study of hepatitis B (HB) vaccine non-responsiveness among health care workers from an endemic area (Taiwan). Liver international: official journal of the International Association for the Study of the Liver 25, 1162-1168, doi: 10.1111/j.1478-3231.2005.01157.x (2005).
30. Panhotra, B. R., Saxena, A. K., Al-Hamrani, H. A. & Al-Mulhim, A. Compliance to hepatitis B vaccination and subsequent development of seroprotection among health care workers of a tertiary care center of Saudi Arabia. American journal of infection control 33, 144-150, doi: 10.1016/j.ajic.2005.01.002 (2005).
31. Kulkarni, P. S. et al. Immunogenicity of a new, low-cost recombinant hepatitis B vaccine derived from Hansenula polymorpha in adults. Vaccine 24, 3457-3460, doi: 10.1016/j.vaccine.2006.02.008 (2006).
32. Estevez, Z. C. et al. Immunogenicity and safety assessment of the Cuban recombinant hepatitis B vaccine in healthy adults. Biologicals: journal of the International Association of Biological Standardization 35, 115-122, doi: 10.1016/j.biologicals.2006.06.001 (2007).
33. Locquet, C., Marande, J. L., Choudat, D. & Vidal-Trecan, G. Hepatitis B vaccination in women healthcare workers: a seroepidemiological survey. European journal of epidemiology 22, 113-119, doi: 10.1007/s10654-006-9094-x (2007).
34. Sabido, M., Gavalda, L., Olona, N. & Ramon, J. M. Timing of hepatitis B vaccination: its effect on vaccine response in health care workers. Vaccine 25, 7568-7572, doi: 10.1016/j.vaccine.2007.08.025 (2007).
35. Oliveira, L. C., Silva, T. E. & Alves, M. H. Response to hepatitis B vaccine in alcoholics without clinically evident liver cirrhosis. Arquivos de gastroenterologia 44, 195-200 (2007).
36. Wolters, B. et al. Comparative evaluation of the immunogenicity of combined hepatitis A and B vaccine by a prospective and retrospective trial. Human vaccines 5, 248-253 (2009).
37. Kevorkyan, A. K. et al. Immune response and immunologic memory in medical personnel vaccinated with hepatitis B vaccine. Folia medica 53, 32-38 (2011).
38. Sheffield, J. S. et al. Efficacy of an accelerated hepatitis B vaccination program during pregnancy. Obstetrics and gynecology 117, 1130-1135, doi: 10.1097/AOG.0b013e3182148efe (2011).
39. De Schryver, A. et al. Comparative immunogenicity of two vaccination schedules of a combined hepatitis A and B vaccine in healthy volunteers. Journal of viral hepatitis 18, e5-10, doi: 10.1111/j.1365-2893.2010.01365.x (2011).
40. Tohme, R. A. et al. Evaluation of hepatitis B vaccine immunogenicity among older adults during an outbreak response in assisted living facilities. Vaccine 29, 9316-9320, doi: 10.1016/j.vaccine.2011.10.011 (2011).
41. Ren, J. J. et al. Immunological effects of a 10-mug dose of domestic hepatitis B vaccine in adults. Journal of Zhejiang University. Science. B 13, 948-954, doi: 10.1631/jzus.B1200179 (2012).
42. Williams, R. E. et al. Hepatitis B vaccination of susceptible elderly residents of long term care facilities during a hepatitis B outbreak. Vaccine 30, 3147-3150, doi: 10.1016/j.vaccine.2012.02.078 (2012).
43. Chathuranga, L. S., Noordeen, F. & Abeykoon, A. M. Immune response to hepatitis B vaccine in a group of health care workers in Sri Lanka. International journal of infectious diseases: IJID: official publication of the International Society for Infectious Diseases 17, e1078-1079, doi: 10.1016/j.ijid.2013.04.009 (2013).
44. Bender, T. J. et al. Hepatitis B vaccine immunogenicity among adults vaccinated during an outbreak response in an assisted living facility-Virginia, 2010. Vaccine 32, 852-856, doi: 10.1016/j.vaccine.2013.12.018 (2014).
45. Thomas, R. J. et al. Prevalence of non-responsiveness to an indigenous recombinant hepatitis B vaccine: a study among South Indian health care workers in a tertiary hospital. Indian journal of medical microbiology 33 Suppl, 32-36, doi: 10.4103/0255-0857.150877 (2015).
46. Nashibi, R. et al. Post-vaccination Immunity Against Hepatitis B Virus and Predictors for Non-responders Among Medical Staff. Jundishapur journal of microbiology 8, e19579, doi: 10.5812/jjm.19579 (2015).
47. Yao, J. et al. Optimal vaccination program for healthy adults in China. Human vaccines & immunotherapeutics, 0, doi: 10.1080/21645515.2015.1053674 (2015).
48. Yao, J. et al. The response of hepatitis B vaccination on seronegative adults with different vaccination schedules. Human vaccines & immunotherapeutics 11, 1102-1107, doi: 10.4161/21645515.2014.985500 (2015).
49. Guyatt, G. et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. Journal of clinical epidemiology 64, 383-394, doi: 10.1016/j.jclinepi.2010.04.026 (2011).
50. Egger, M., Davey, S. G., Schneider, M. & Minder, C. Bias in meta-Analysis detected by a simple, graphical test. BMJ. Bmj 315, 477-477 (1997).
51. Zeeshan, M. et al. Evaluation of immune response to Hepatitis B vaccine in health care workers at a tertiary care hospital in Pakistan: an observational prospective study. BMC infectious diseases 7, 120, doi: 10.1186/1471-2334-7-120 (2007).
52. Sangfelt, P., Uhnoo, I., Reichard, O. & Weiland, O. A low-dose intradermal hepatitis B vaccine programme in health-care workers and students is highly effective and cost saving: a retrospective follow-up survey in the clinical setting. Scandinavian journal of gastroenterology 43, 465-472, doi: 10.1080/00365520701733806 (2008).
53. Kanda, N. & Tamaki, K. Estrogen enhances immunoglobulin production by human PBMCs. The Journal of allergy and clinical immunology 103, 282-288 (1999).
54. Kanda, N., Tsuchida, T. & Tamaki, K. Testosterone inhibits immunoglobulin production by human peripheral blood mononuclear cells. Clinical and experimental immunology 106, 410-415 (1996).
55. Klein, S. L., Marriott, I. & Fish, E. N. Sex-based differences in immune function and responses to vaccination. Transactions of the Royal Society of Tropical Medicine and Hygiene 109, 9-15, doi: 10.1093/trstmh/tru167 (2015).
56. Saunders, J. B., Davis, M. & Williams, R. Do women develop alcoholic liver disease more readily than men? British medical journal 282, 1140-1143 (1981).
57. Hohler, T. et al. Differential genetic determination of immune responsiveness to hepatitis B surface antigen and to hepatitis A virus: a vaccination study in twins. Lancet 360, 991-995, doi: 10.1016/S0140-6736(02)11083-X (2002).
58. Mentzer, A. J., O'Connor, D., Pollard, A. J. & Hill, A. V. Searching for the human genetic factors standing in the way of universally effective vaccines. Philosophical transactions of the Royal Society of London. Series B, Biological sciences 370, doi: 10.1098/rstb.2014.0341 (2015).